AstraZeneca has reported positive data from pre-specified sub-analyses of its Farxiga (dapagliflozin) drug in the Phase III DECLARE-TIMI 58 clinical trial involving type-2 diabetes (T2D) patients with prior heart attack history.

The trial data showed that Farxiga led to a 16% decrease in the relative risk of major adverse cardiovascular events (MACE) when compared to placebo.

The drug also lowered the relative risk of hospitalisation due to heart failure (hHF), irrespective of the participants’ ejection fraction (EF) status.

Farxiga is designed as a selective inhibitor of human sodium-glucose co-transporter 2 (SGLT2). It is indicated as monotherapy and a combination therapy to improve glycaemic control in adults with T2D.

“These data build upon the existing evidence of the cardio-renal effects of Farxiga, with important new evidence on heart failure and MACE.”

The drug is not indicated to decrease the risk of CV events, heart failure or death.

DECLARE-TIMI 58 compared the drug with placebo in CV outcomes of patients who are at risk of CV events, including those with multiple CV risk factors or established CV disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The randomised, double-blinded, placebo-controlled, multi-centre trial was conducted in more than 17,000 participants at 882 sites in 33 countries.

Previous DECLARE-TIMI 58 results, reported in November last year, demonstrated that the drug significantly minimised the risk of hHF or CV death by 17%, compared to placebo.

AstraZeneca R&D BioPharmaceuticals late Cardiovascular, Renal, and Metabolism head Elisabeth Björk said: “These data build upon the existing evidence of the cardio-renal effects of Farxiga, with important new evidence on heart failure and MACE.

“Heart failure is one of the most common early cardiovascular complications of type-2 diabetes. Despite advances in healthcare, it remains as life-threatening and prevalent as the combined incidence of the top-four most common forms of cancer. Therefore, more needs to be done for patients.”

The latest findings have been presented at the American College of Cardiology’s 68th Annual Scientific Session held in New Orleans, USA and published in the Circulation journal.